Adding Palbociclib to Maintenance Anti-HER2 and Endocrine Therapies Improves PFS Over Standard Therapy in Patients with HR-positive, HER2-positive MBC By Ogkologos - February 5, 2026 483 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PATINA study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR FDA Expands Early Breast Cancer Indication for Abemaciclib with Endocrine Therapy March 16, 2023 Immunotherapy’s Skin Side Effects: Are Microbes to Blame? July 13, 2022 Revumenib Shows Promise in Treating Advanced Acute Myeloid Leukemia April 18, 2023 EMA Recommends Granting a Marketing Authorisation for Tucatinib December 22, 2020 Load more HOT NEWS FDA Approves Lorlatinib for Metastatic ALK-positive Non-Small Cell Lung Cancer Evaluating Targeted Therapy for People With Advanced Gastric or Gastroesophageal Junction... Metastatic Breast Cancer Patient Denied Chemotherapy Treatment During COVID-19 Outbreak How Becky is helping her children to keep their dad’s memory...
